Accord brings in Paul Burden for UK role

Paul Burden (pictured, above) has been appointed associate vice president and country head of Accord UK, effective immediately.

The fully-owned subsidiary of Intas Pharmaceuticals has landed an experienced operator, with more than 26 years of experience in UK and European pharma and a strong track record of leading commercial strategy, driving growth and building high-performing teams across both generics and speciality pharma.

Most recently, Mr Burden served as vice president of German generics and consumer healthcare major STADA Arzneimittel (SAZ: Xetra), where he led strategy and execution across established brands, generics and speciality pharmaceuticals.

Before this, he held a number of senior leadership roles at privately-held UK firm Advanz Pharma, including chief commercial officer Europe and president UK & Ireland, and he has previously worked at the likes of Teva Pharmaceutical Industries (NYSE: TEVA), Mylan and Novartis (NOVN: VX).

Mr Burden is vice chair and chair-elect of the Medicines UK Board, an industry board that represents generic medicine manufacturers, promoting competition, increasing access and creating savings for the National Health Service.

Jamie Sparrow, senior vice president, head of commercial, Europe and MENA at Accord Healthcare, said: “We are excited to welcome Paul to Accord. His experience and leadership will be instrumental in supporting our strategic drive in the UK and strengthening our position in this critical market.”